Company intelligence / Profile preview

Curasight

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Curasight’s lead diagnostic program, uTRACE®, has completed or is undergoing several investigator-led Phase II trials in multiple cancers. It has demonstrated safety and efficacy in humans. The therapeutic program, uTREAT®, has shown promising preclinical results; a Phase I trial in glioblastoma began in mid–2025 with preliminary efficacy data expected by late–2025.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalPeptide (for imaging agents)Small molecule (potentially for some radioligands)
Industry: Biotech

Drug pipeline

4 assets

68Ga-NOTA-AE105

3 more assets in the full pipeline.

Request access →

Partnerships

Curium Inc. – exclusive global license/collaboration agreement for development/commercialization of uTRACE® in prostate cancerPentwater Capital as strategic shareholder

Beyond the preview

Go deeper on Curasight.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curasight.

Explore the full profile